Asciminib, the first BCR::ABL inhibitor targeting the myristoyl pocket rather than the ATP-binding site of the ABL kinase domain, was approved by the European Commission on 25 August 2022, for the treatment of patients with CP-CML after failure on two or more TKIs [47,48,49] (with approval not yet sought for patients with the T315I mutation). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.